Effects of enrichment strategies on outcome of adrecizumab treatment in septic shock: Post-hoc analyses of the phase II adrenomedullin and outcome in septic shock 2 trial.

ABSTRACT:

Purpose

Adrecizumab, a non-neutralizing antibody of adrenomedullin (ADM) was recently investigated regarding its potential to restore endothelial barrier function in septic shock patients with high plasma ADM levels. Circulating dipeptidyl peptidase 3 (cDPP3), a protease involved in the degradation of several cardiovascular mediators, represents another biological pathway strongly associated with outcome in septic shock, although unrelated to ADM. Therefore, the prognosis of patients with elevated cDPP3 may not be influenced by Adrecizumab. Also, time until initiation of treatment may influence efficacy.

Objective

To evaluate effects of cDPP3-based enrichment on treatment efficacy of Adrecizumab.

Materials and methods

Post-hoc analysis of AdrenOSS-2, a phase-II

SUBMITTER: van Lier D 

PROVIDER: S-EPMC9751049 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature